Triton Systems is a Global Business Venture company that successfully launches innovative products and solutions in emerging markets worldwide. We invest in new technologies through in-house incubation and external partnerships – creating thriving businesses from novel ideas.

Business Ventures

Triton commercializes innovative technologies and transforms them into successful businesses. From cancer treatment to flame retardant plastic to waste water management, we impact global markets creating $3.8 Billion in shareholder value.

Ventures Include:

Aduro Biotech

Aduro Biotech (Aduro), a Triton launched company formed in 2010, stays at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases.

FRX Polymers, Inc.

FRX Polymers, Inc., a (formed by Triton in 2007) manufactures Nofia® polyphosphonates - fire resistant plastics. Nofia products are fully transparent, high flowing and, due to their high phosphorus content, are inherently flame retardant. 

Emefcy

Emefcy specializes in developing energy-efficient wastewater treatment solutions. The company’s innovative Membrane Aerated Biofilm Reactor (MABR) technology is installed at sites around the world.

Sensera

Sensera is an integrated, fast turnaround client-specific designer and manufacturer of specialized high performance microsensors and micro-fabricated components for the Healthcare, Industrial, Defense and Aerospace markets.

Emerging Technologies

Key to our process is to research, identify and incubate emerging technologies that are in line with our strategic market focus. Through our in-house incubation operations or through outside partnerships and adopted technologies, we provide market driven solutions that effect the world around us. Emerging technologies include:

Featured Incubated Products

Traceptor™ Preconcentrator

A Plug and Play ‘Sensitivity Amplifier’ that enables chemical sensors for threat and contraband detection.

MEMS Sensors & Manufacturing

Sensera designs, engineers and manufactures MEMS-based sensors and other devices for industrial, medical and defense applications.

FRA Composites
(Fiber Reinforced Aluminum)

Triton FRA Composites is a fiber reinforced aluminum composite that offers light weight and high strength alternatives to heavy steel for bearing applications.

Latest News

Triton Receives Tibbetts Award at White House Ceremony

January 10, 2017, Chelmsford, MA:Triton Systems, Inc. (Triton) announced today that it has received a Tibbetts Award from the US Small Business Administration during a White House ceremony in Washington D.C. This prestigious national award award is given to companies who have successfully leveraged Small Business Innovation Research (SBIR) grants and have generated great value to the firm and to the nation.

Read More

Sensera Achieves ISO9001 Certification

May 16, 2017, Chelmsford, MA: Sensera Ltd (Sensera) (ASX:SE1), a microsensor and microcomponent business focused on the design and production of specialized high performance components for the healthcare, industrial, military and aerospace markets is pleased to announce it has earned certification from the International Organization for Standardization (ISO), effective April 20, 2017. This registration demonstrates Sensera’s leadership and strong commitment to the implementation of effective quality management systems.

Read More

 

 

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma

Second Phase 2 Clinical Collaboration between the Two Companies to Evaluate CRS-207/Pembrolizumab Combination

BERKELEY, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today the expansion of its clinical collaboration with Merck (known as MSD outside the United States and Canada) to include an additional Phase 2 clinical trial. The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with malignant pleural mesothelioma (MPM) whose disease progressed following prior treatment.

Read More

 

Emefcy and RWL Water Announce Binding Sale and Purchase Agreement

Melbourne, Australia and New York, NY: Emefcy Group Limited (ASX: EMC) (“Emefcy”) and RWL Water LLC (“RWL Water”) announced today that they have executed a binding Sale and Purchase Agreement (“SPA”) pursuant to which the two companies would combine. Following closing, the merged company would be renamed Fluence Corporation Limited (“Fluence”).

Read More